Cell and Gene Therapy
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
Sangamo Therapeutics
PR-M04-19-NI-012Apr 03, 2019
Clinical Trial
Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A
Sangamo Therapeutics
PR-M08-18-NI-113Aug 29, 2018
Oncology
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Sangamo Therapeutics
PR-M02-18-NI-95Feb 26, 2018
Innovation
Pfizer Collaborates with Gene Editing Company Sangamo Therapeutics on Hemophilia A Treatment
Nigel Walker
Nice Insight
PAO-M05-17-NI-022May 19, 2017